表紙
市場調查報告書

激躁性結腸症:開發中產品分析

Irritable Bowel Syndrome - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 232842
出版日期 內容資訊 英文 162 Pages
訂單完成後即時交付
價格
Back to Top
激躁性結腸症:開發中產品分析 Irritable Bowel Syndrome - Pipeline Review, H2 2019
出版日期: 2019年12月16日內容資訊: 英文 162 Pages
簡介

激躁性結腸症(IBS)是伴隨慢性或復發性免疫反應的症狀,或是消化管發炎的用語。症候有腹部的痙攣和疼痛,有血的腹瀉,體重減輕,食慾不振,及發燒等。原因有年齡,家族病史,抽煙,止痛藥等。可使用皮質類固醇,免疫抑制劑,抗生素,鎮壓藥等來治療。

本報告提供全球各國治療激躁性結腸症(IBS)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

激躁性結腸症概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 大學/研究機關所開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

激躁性結腸症的治療藥開發企業

  • 4D Pharma PLC
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Alfa Wassermann SpA
  • Allergan Plc
  • Ardelyx Inc
  • Astellas Pharma Inc.
  • CJ HealthCare Corp
  • ConSynance Therapeutics Inc
  • Cosmo Pharmaceuticals NV
  • Dong-A ST Co., Ltd.
  • Eisai
  • Enterome Bioscience SA
  • GlaxoSmithKline Plc
  • Innovative Med Concepts LLC
  • Ironwood Pharmaceuticals Inc
  • Kissei藥品
  • Lexicon Pharmaceuticals Inc
  • Napo Pharmaceuticals Inc
  • Pfizer Inc
  • RaQualia Pharma Inc
  • RedHill Biopharma Ltd
  • SK Biopharmaceuticals Co Ltd
  • 大日本住友製藥
  • Synergy Pharmaceuticals Inc
  • Synthetic Biologics Inc
  • Vitality Biopharma Inc

藥物簡介

激躁性結腸症:暫停中的計劃

激躁性結腸症:開發中止的產品

激躁性結腸症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11615IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Pipeline Review, H2 2019, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that affects large intestine (colon). Symptoms include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite and constipation. These symptoms can be triggered by food, stress and hormones. Risk factors include age and family history. Treatment includes anti-diarrheal, anticholinergic, antidepressant and antibiotics medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 11, 6, 1, 10, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Irritable Bowel Syndrome - Overview
  • Irritable Bowel Syndrome - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Irritable Bowel Syndrome - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Irritable Bowel Syndrome - Companies Involved in Therapeutics Development
  • 4D Pharma Plc
  • Allergan Plc
  • Ardelyx Inc
  • AsiaBiome
  • Axim Biotechnologies Inc
  • Bausch Health Companies Inc
  • Biomica
  • Boston Pharmaceuticals Inc
  • CinRx Pharma LLC
  • ConSynance Therapeutics Inc
  • Cosmo Pharmaceuticals NV
  • Dong-A ST Co Ltd
  • Eisai Co Ltd
  • Enterome Bioscience SA
  • Exeliom Biosciences SAS
  • GEXVal Inc
  • ImmuneBiotech AB
  • Ironwood Pharmaceuticals Inc
  • Jiangsu Aosaikang Pharmaceutical Co Ltd
  • LTT Bio-Pharma Co Ltd
  • Merck & Co Inc
  • Metacrine Inc
  • MGC Pharmaceuticals Ltd
  • Napo Pharmaceuticals Inc
  • Novome Biotechnologies Inc
  • Oncocross Co Ltd
  • Orphomed Inc
  • Outpost Medicine Ltd
  • Protagonist Therapeutics Inc
  • RaQualia Pharma Inc
  • RedHill Biopharma Ltd
  • Renexxion LLC
  • Sentia Medical Sciences Inc
  • Serentrix LLC
  • Synthetic Biologics Inc
  • Velicept Therapeutics Inc
  • Vitality Biopharma Inc
  • Irritable Bowel Syndrome - Drug Profiles
  • AB-02 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Biologics for Irritable Bowel Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BMC-426 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BOS-589 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Canchew Plus - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cannabidiol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CIN-103 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • crofelemer DR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CSTI-300 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DA-6886 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs for Inflammation and Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • E-2508 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EB-410 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EB-420 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GXV-004 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IB-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • linaclotide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lovastatin MR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LT-4006 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MET-409 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MRx-1234 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • naronapride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NBX-1650 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OC-211 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ondansetron hydrochloride CR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OP-687 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ORP-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • plecanatide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PR-38 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Ramosetron Hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rifamycin sodium CR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RQ-00310941 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SER-224 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit TPH1 for Gastrointestinal, Metabolic Disorder and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • solabegron - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptides to Agonize DOR1 and MOR1 for Irritable Bowel Syndome with Diarrhea - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptides to Antagonize CRHR1 and CRHR2 for Gastrointestinal Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tenapanor hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VB-100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VB-210 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • vibegron - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Irritable Bowel Syndrome - Dormant Projects
  • Irritable Bowel Syndrome - Discontinued Products
  • Irritable Bowel Syndrome - Product Development Milestones
  • Featured News & Press Releases
  • Oct 28, 2019: Salix Pharmaceuticals to present new clinical data on TRULANCE (Plecanatide) at the American College of Gastroenterology (ACG) Annual Meeting
  • Oct 18, 2019: Cipher Pharmaceuticals receives Health Canada approval For Trulance (Plecanatide)
  • Sep 26, 2019: Synthetic Biologics strengthens U.S. patent coverage of SYN-010, intended for the novel treatment of irritable bowel syndrome with constipation (IBS-C)
  • Sep 12, 2019: Ardelyx receives FDA Approval for IBSRELA (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the treatment of Irritable Bowel Syndrome with Constipation
  • Aug 15, 2019: Alfasigma USA announces ZELNORM (tegaserod) now available for treatment of irritable bowel syndrome with constipation
  • Jul 22, 2019: Ironwood Pharmaceuticals Allergan provides update on its ANDA Lawsuit
  • Jun 26, 2019: Knight announces filing of New Drug Submission for Ibsrela in Canada
  • Jun 20, 2019: Ironwood and Allergan's LINZESS trial meets primary endpoint
  • May 22, 2019: Sentia Medical Sciences awarded approximately $1.8 million phase II small business innovation research (SBIR) grant to develop Astressins for the treatment of irritable bowel syndrome (IBS)
  • May 14, 2019: Salix Pharmaceuticals presents data on TRULANCE at Digestive Disease Week
  • May 09, 2019: Ironwood Pharmaceuticals to highlight linaclotide data at Digestive Disease Week 2019
  • Apr 01, 2019: FDA approves the reintroduction of Zelnorm™ (tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in women under 65
  • Jan 18, 2019: Linzess (linaclotide) approved in China for the treatment of irritable bowel syndrome with constipation
  • Jan 15, 2019: Ironwood Pharmaceuticals announces approval of LINZESS (linaclotide) in China for the treatment of adults with IBS-C
  • Jan 07, 2019: Jaguar Health Provides Fourth Quarter 2018 Commercial Sales Updates
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Irritable Bowel Syndrome, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Irritable Bowel Syndrome - Pipeline by 4D Pharma Plc, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Allergan Plc, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Ardelyx Inc, H2 2019
  • Irritable Bowel Syndrome - Pipeline by AsiaBiome, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Axim Biotechnologies Inc, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Bausch Health Companies Inc, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Biomica, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Boston Pharmaceuticals Inc, H2 2019
  • Irritable Bowel Syndrome - Pipeline by CinRx Pharma LLC, H2 2019
  • Irritable Bowel Syndrome - Pipeline by ConSynance Therapeutics Inc, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Cosmo Pharmaceuticals NV, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Dong-A ST Co Ltd, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Eisai Co Ltd, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Enterome Bioscience SA, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Exeliom Biosciences SAS, H2 2019
  • Irritable Bowel Syndrome - Pipeline by GEXVal Inc, H2 2019
  • Irritable Bowel Syndrome - Pipeline by ImmuneBiotech AB, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals Inc, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, H2 2019
  • Irritable Bowel Syndrome - Pipeline by LTT Bio-Pharma Co Ltd, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Merck & Co Inc, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Metacrine Inc, H2 2019
  • Irritable Bowel Syndrome - Pipeline by MGC Pharmaceuticals Ltd, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Novome Biotechnologies Inc, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Oncocross Co Ltd, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Orphomed Inc, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Outpost Medicine Ltd, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Protagonist Therapeutics Inc, H2 2019
  • Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc, H2 2019
  • Irritable Bowel Syndrome - Pipeline by RedHill Biopharma Ltd, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Renexxion LLC, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Sentia Medical Sciences Inc, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Serentrix LLC, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Synthetic Biologics Inc, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Velicept Therapeutics Inc, H2 2019
  • Irritable Bowel Syndrome - Pipeline by Vitality Biopharma Inc, H2 2019
  • Irritable Bowel Syndrome - Dormant Projects, H2 2019
  • Irritable Bowel Syndrome - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Irritable Bowel Syndrome - Dormant Projects, H2 2019 (Contd..2), H2 2019
  • Irritable Bowel Syndrome - Dormant Projects, H2 2019 (Contd..3), H2 2019
  • Irritable Bowel Syndrome - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Irritable Bowel Syndrome, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top